Cigarette use is increasing among people with illicit substance use disorders in the United States, 2002–14: emerging disparities in vulnerable populations

Addiction

Volumn 113, Issue 4, 2018, Pages 719-728

  Weinberger, Andrea H ^a,b   Gbedemah, Misato ^c   Wall, Melanie M ^d,e   Hasin, Deborah S ^d,e,f   Zvolensky, Michael J ^g,h   Goodwin, Renee D ^c,d  

^a YESHIVA UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d Columbia University ^*  (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f University of Houston ^*  (United States)

^g UNIVERSITY OF HOUSTON   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cannabis use disorders; cigarettes; epidemiology; NSDUH; smoking; substance use disorders

Indexed keywords

ADOLESCENT; ADULT; CHILD; CIGARETTE SMOKING; CROSS-SECTIONAL STUDY; DRUG DEPENDENCE; FEMALE; HEALTH DISPARITY; HUMAN; MALE; MIDDLE AGED; UNITED STATES; VULNERABLE POPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CIGARETTE SMOKING; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; MALE; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS; UNITED STATES; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 85038249492     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.14082     Document Type: Article

References (63)

1. World Health Organization (WHO). WHO Global Report: Mortality Attributable to Tobacco. Geneva, Switzerland: WHO Press; 2012.
2. United States Department of Health and Social Services (USDHHS). The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: USDHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
3. Carter B. D., Abnet C. C., Feskanich D., Freedman N. D., Hartge P., Lewis C. E. et al. Smoking and mortality—beyond established causes. N Engl J Med 2015; 372: 631–640.
4. Jamal A., King B. A., Neff L. J., Whitmill J., Babb S. D., Graffunder C. M. Current cigarette smoking among adults—United States, 2005–2015. Morb Mort Wkly Rep 2016; 65: 1205–1211.
5. Ng M., Freeman M. K., Fleming T. D., Robinson M., Dwyer-Lindgren L., Thomson B. et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA 2014; 311: 183–192.
6. Global Burden of Disease (GBD) 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017; 389: 1885–1906.
7. Smith P. H., Mazure C. M., McKee S. A. Smoking and mental illness in the US population. Tob Control 2014; 23: e147–53.
8. Szatkowski L., McNeill A. Diverging trends in smoking behaviors according to mental health status. Nicotine Tob Res 2015; 17: 356–360.
9. Grant B. F., Saha T. D., Ruan W. J., Goldstein R. B., Chou S. P., Jung J. et al. Epidemiology of DSM-5 drug use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions–III. JAMA Psychiatry 2016; 73: 39–47.
10. Weinberger A. H., Funk A. P., Goodwin R. D. A review of epidemiologic research on smoking behavior among persons with alcohol and illicit substance use disorders. Prev Med 2016; 92: 148–159.
11. Hasin D. S., Saha T. D., Kerridge B. T., Goldstein R. B., Chou S. P., Zhang H. et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 2015; 72: 1235–1242.
12. Hurt R. D., Offord K. P., Croghan I. T., Gomez-Dahl L., Kottke T. E., Morse R. M. et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA 1996; 275: 1097–1103.
13. Hser Y. I., McCarthy W. J., Anglin M. D. Tobacco use as a distal predictor of mortality among long-term narcotic addicts. Prev Med 1994; 23: 61–69.
14. Ouellet-Plamondon C., Mohamed N. S., Sharif-Razi M., Simpkin E., George T. P. Treatment of comorbid tobacco addiction in substance use and psychiatric disorders. Curr Addict Rep 2014; 1: 61–68.
15. Cohn A., Elmasry H., Niaura R. Facility-level, state, and financial factors associated with changes in the provision of smoking cessation services in US substance abuse treatment facilities: results from the National Survey of Substance Abuse Treatment Services 2006 to 2012. J Subst Abuse Treat 2017; 77: 107–114.
16. World Health Organization (WHO). Cannabis. WHO Press: Geneva, Switzerland; 2017 Available at: http://www.who.int/substance_abuse/facts/cannabis/en/ (accessed 5 November 2017) (Archived at http://www.webcitation.org/6vSXxIIKk).
17. Grant B., Stinson F., Dawson D., Chou S., Dufour M., Compton W. et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61: 807–816.
18. Hasin D. S., Kerridge B. T., Saha T. D., Huang B., Pickering R., Smith S. M. et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III. Am J Psychiatry 2016; 173: 588–599.
19. Azofeifa A., Mattson M. E., Schauer G., McAfee T., Grant A., Lyerla R. National estimates of marijuana use and related indicators—National Survey on Drug Use and Health, United States, 2002–2014. Morb Mort Wkly Rep Surveill Summ 2016; 65: 1–28.
20. Hasin D. S., Sarvet A. L., Cerdá M., Keyes K. M., Stohl M., Galea S. et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991–1992 to 2012–2013. JAMA Psychiatry 2017; 74: 579–588.
21. Compton W. M., Han B., Jones C. M., Blanco C., Hughes A. Marijuana use and use disorders in adults in the USA, 2002–2014: analysis of annual cross-sectional surveys. Lancet Psychiatry 2016; 3: 954–964.
22. Grucza R. A., Agrawal A., Krauss M. J., Cavazos-Behg P. A., Bierut L. I. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry 2016; 73: 300–301.
23. Maxwell J. C., Mendelson B. What do we know about the impact of the laws related to marijuana? J Addict Med 2016; 10: 3–12.
24. Williams J., Bretteville-Jensen A. L. Does liberalizing cannabis laws increase cannabis use? J Health Econ 2014; 36: 20–32.
25. Hall W., Lynskey M. Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction 2016; 111: 1764–1773.
26. Hajizadeh M. Legalizing and regulating marijuana in Canada: review of potential economic, social, and health impacts. Int J Health Policy Manag 2016; 5: 453–456.
27. Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey on Drug Use and Health, 2013. Codebook. Rockville, MD: SAMHSA; 2014.
28. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. In: DSM-IV, 4th edn. Washington, DC: APA; 1994.
29. Bieler G. S., Brown G. G., Williams R. L., Brogan D. J. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol 2010; 171: 618–623.
30. Guydish J., Passalacqua E., Tajima B., Chan M., Chun J., Bostrom A. Smoking prevalence in addiction treatment: a review. Nicotine Tob Res 2011; 13: 401–411.
31. Guydish J., Passalacqua E., Pagano A., Martínez C., Le T., Chun J. et al. An international systematic review of smoking prevalence in addiction treatment. Addiction 2016; 111: 220–230.
32. Tacke U., Wolff K., Finch E., Strang J. The effect of tobacco smoking on subjective symptoms of inadequacy (‘not holding’) of methadone dose among opiate addicts in methadone maintenance treatment. Addict Biol 2001; 14: 137–145.
33. Blanco C., Okuda M., Wang S., Liu S. M., Olfson M. Testing the drug substitution switching-addictions hypothesis. A prospective study in a nationally representative sample. JAMA Psychiatry 2014; 71: 1246–1253.
34. Kandel D., Kandel E. The Gateway hypothesis of substance abuse: developmental, biological and societal perspectives. Acta Paediatr 2015; 104: 130–137.
35. Brook D. W., Brook J. S., Zhang C., Cohen P., Witeman M. Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch Gen Psychiatry 2002; 59: 1039–1044.
36. Weinberger A. H., Platt J., Esan H., Galea S., Erlich D., Goodwin R. D. Cigarette smoking is associated with increased risk of substance use disorder relapse: a nationally representative, prospective longitudinal investigation. J Clin Psychiatry 2017; 78: e152–60.
37. McClure E. A., Campbell A. N., Pavlicova M., Hu M., Winhusen T., Vandrey R. G. et al. Cigarette smoking during substance use disorder treatment: secondary outcomes from a National Drug Abuse Treatment Clinical Trials Network study. J Subst Abuse Treat 2015; 53: 39–46.
38. Lemon S. C., Friendmann P. D., Stein M. D. The impact of smoking cessation on drug abuse treatment outcome. Addict Behav 2003; 28: 1323–1331.
39. Baca C. T., Yahne C. E. Smoking cessation during substance abuse treatment: what you need to know. J Subst Abuse Treat 2009; 36: 205–219.
40. Winhusen T. M., Kropp F., Theobald J., Lewis D. F. Achieving smoking abstinence is associated with decreased cocaine use in cocaine-dependent patients receiving smoking-cessation treatment. Drug Alcohol Depend 2014; 134: 391–395.
41. Tsoh J. Y., Chi F. W., Mertens J. R., Weisner C. M. Stopping smoking during first year of substance use treatment predicted 9-year alcohol and drug treatment outcomes. Drug Alcohol Depend 2011; 114: 110–118.
42. Prochaska J. J., Delucchi K., Hall S. M. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol 2004; 72: 1144–1156.
43. McKelvey K., Thrul J., Ramo D. Impact of quitting smoking and smoking cessation treatment on substance use outcomes: an updated and narrative review. Addict Behav 2017; 65: 161–170.
44. Das S., Hickman N. J., Prochaska J. J. Treating smoking in adults with co-occurring acute psychiatric and addictive disorders. J Addict Med 2017; 11: 273–279.
45. Levy D. T., Chaloupka F., Gitchell J. The effects of tobacco control policies on smoking rates: a tobacco control scorecard. J Public Health Manag Pract 2004; 10: 338–353.
46. Ekpu V. U., Brown A. K. The economic impact of smoking and of reducing smoking prevalence: review of evidence. Tob Use Insights 2015; 8: 1–35.
47. Fiore M. C., Jaén C. R., Baker T. B., Bailey W. C., Benowitz N. L., Curry S. J. et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services; 2008.
48. Richter K. P., Ahluwalia J. S. A case for addressing cigarette use in methadone nad other opioid treatment programs. J Addict Dis 2000; 19: 35–52.
49. Nahvi S., Ning Y., Segal K. S., Richter K. P., Arnsten J. H. Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial. Addiction 2014; 109: 1554–1563.
50. Rohsenow D. J., Martin R. A., Tidey J. W., Colby S. M., Monti P. M. Treating smokers in substance treatment with contingent vouchers, nicotine replacement and brief advice adapted for sobriety settings. J Subst Abuse Treat 2017; 72: 72–79.
51. Apollonio D., Philipps R., Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev 2016; 11: CD010274.
52. Muilenburg J. L., Laschober T. C., Eby L. T. Organizational factors as predictors of tobacco cessation pharmacotherapy adoption in addiction treatment programs. J Addict Med 2014; 8: 59–65.
53. Knudsen H. K., Muilenburg J., Eby L. T. Sustainment of smoking cessation programs in substance use disorder treatment organizations. Nicotine Tob Res 2013; 15: 1060–1068.
54. Pagano A., Tajima B., Guydish J. Barriers and facilitators to tobacco cessation in a nationwide sample of addiction treatment programs. J Subst Abuse Treat 2016; 67: 22–29.
55. Laschober T. C., Muilenburg J. L., Eby L. T. Factors linked to substance use disorder counselors' (non)implementation likelihood of tobacco cessation 5 A's, counseling, and pharmacotherapy. J Addict Behav Ther Rehabil 2015; 4: 134.
56. Martin R. A., Cassidy R. N., Murphy C. M., Rohsenow D. J. Barriers to quitting smoking among substance dependent patients predict smoking cessation treatment outcome. J Subst Abuse Treat 2016; 64: 7–12.
57. Rohsenow D. J., Tidey J. W., Kahler C. W., Martin R. A., Colby S. M., Sirota A. D. Intolerance for withdrawal discomfort and motivation predict voucher-based smoking treatment outcomes for smokers with substance use disorders. Addict Behav 2015; 43: 18–24.
58. McHugh R. K., Votaw V. R., Fulciniti F., Connery H. S., Griffin M. L., Monti P. M. et al. Perceived barriers to smoking cessation among adults with substance use disorders. J Subst Abuse Treat 2017; 74: 48–53.
59. Campbell B. K., Le T., Tajima B., Guydish J. Quitting smoking during substance use disorders treatment: patient and treatment-related variables. J Subst Abuse Treat 2017; 73: 40–46.
60. Guydish J., Tajima B., Pramod S., Le T., Gubner N. R., Campbell B. et al. Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment. Drug Alcohol Depend 2016; 166: 93–99.
61. Wang T. W., Kenemer B., Tynan M. A., Singh T., King B. Consumption of combustible and smokeless tobacco—United States, 2000–2015. Morb Mort Wkly Rep 2016; 65: 1357–1363.
62. Gorber S. C., Schofield-Hurwitz S., Hardt J., Levasseur G., Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res 2009; 11: 12–24.
63. Fendrich M., Johnson T. P., Wislar J. S., Hubbell A., Spiehler V. The utility of drug testing in epidemiological research: results from a general population survey. Addiction 2004; 99: 197–208.